Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

BSH 2023 | Long-term safety and efficacy of eculizumab and ravulizumab in patients with PNH

Talha Munir • 24 Apr 2023
BSH 2023
Non-Malignant Paroxysmal Nocturnal Hemoglobinuria Antibodies Eculizumab Ravulizumab

In this video, Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, comments on the safety and efficacy of eculizumab and ravulizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), based on results from a UK experience. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Talha Munir

The Phase III STATIC trial: stopping therapy to avoid treatment resistance in CLL 1:30
The Phase III STATIC trial: stopping therapy to avoid treatment resistance in CLL
Talha Munir • 14 Sep 2025
The comparative efficacy of zanubrutinib versus fixed-duration AV in frontline CLL 1:33
The comparative efficacy of zanubrutinib versus fixed-duration AV in frontline CLL
Talha Munir • 14 Sep 2025
MRD-guided ibrutinib-venetoclax versus ibrutinib or FCR for previously untreated CLL: FLAIR trial 1:39
MRD-guided ibrutinib-venetoclax versus ibrutinib or FCR for previously untreated CLL: FLAIR trial
Talha Munir • 14 Sep 2025
Using MRD-driven therapy in CLL: current and future applications 1:33
Using MRD-driven therapy in CLL: current and future applications
Talha Munir • 8 Dec 2024

Related Videos

Acute chest syndrome in sickle cell disease: pathophysiology, management, and prevention 4:49
Acute chest syndrome in sickle cell disease: pathophysiology, management, and prevention
Subarna Chakravorty • 3 Nov 2025
The role of inflammation in SCD pathophysiology and potential avenues for targeting it 6:48
The role of inflammation in SCD pathophysiology and potential avenues for targeting it
Subarna Chakravorty • 3 Nov 2025
The management of thalassemia in India 2:16
The management of thalassemia in India
Shruti Kakkar • 15 Oct 2025
The potential role of thalidomide in the treatment of thalassemia 2:33
The potential role of thalidomide in the treatment of thalassemia
Shruti Kakkar • 15 Oct 2025
The content of VJHemOnc is intended for healthcare professionals